<DOC>
	<DOCNO>NCT02023879</DOCNO>
	<brief_summary>Primary Objective : To demonstrate reduction low-density lipoprotein cholesterol ( LDL-C ) regimen alirocumab include start dose 150 mg every 4 week ( Q4W ) add-on non-statin lipid modifying background therapy monotherapy comparison placebo participant primary hypercholesterolemia treat statin . Secondary Objective : - To evaluate effect lipid parameter alirocumab 150 mg Q4W versus placebo . - To evaluate safety tolerability alirocumab 150 mg Q4W . Alirocumab 75 mg Q2W add calibrator arm .</brief_summary>
	<brief_title>Phase III Study To Evaluate Alirocumab Patients With Hypercholesterolemia Not Treated With Statin ( ODYSSEY CHOICE II )</brief_title>
	<detailed_description>The core study duration approximately 35 week per participant ( screen : 3 week , double-blind treatment period : 24 week ; follow-up : 8 week ) . Participants successfully complete treatment period possibility participate optional open-label treatment period alirocumab 150 mg Q4W second quarter 2017 drug commercially available country , whatever come first .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Participants primary hypercholesterolemia ( heterozygous familial hypercholesterolemia [ heFH ] nonFH ) adequately control nonstatin LMT ( either ezetimibe fenofibrate ) diet alone . Exclusion criterion : LDLC &lt; 70 mg/dL ( 1.81 mmol/L ) screen statin intolerant participant high cardiovascular ( CV ) risk ; LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) screen statin intolerant participant high moderate CV risk , participant fulfil statin intolerant definition moderate CV risk ; LDLC ≥160 mg/dL ( ≥4.1 mmol/L ) screen participant receive diet , participant fulfil statin intolerant definition moderate CV risk receive nonstatin LMT . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>